Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceMIL:1TWST +0.64%47 Gross Margin % is 52.76% as of Jun. 2026, which is 54% above its 10-year median of 34.23. GuruFocus rates MIL:1TWST with a GF Score™ of 47/100 and a GF Value™ of €46.60 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Twist Bioscience ranks better than 50% on this metric.
The historical rank and industry rank for Twist Bioscience's Gross Margin % or its related term are showing as below:
MIL:1TWST'
s Gross Margin % Range Over the Past 10 Years
Min: -315.2 Med: 34.23 Max: 51.97
Current: 51.97
During the past 10 years, the highestGross Margin % of Twist Bioscience was 51.97%. The lowest was -315.20%. And the median was 34.23%.
MIL:1TWST's Gross Margin % is ranked better than 50% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.775
vs MIL:1TWST: 51.97
Twist Bioscience had a gross margin of 52.76% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Twist Bioscience was 7.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Twist Bioscience had a gross margin of 52.76% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Twist Bioscience Gross Margin % Related Terms
Twist Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1TWST vs BLLN, SHC, RDNT: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Twist Bioscience (MIL:1TWST) has a Gross Margin % of 52.76% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Twist Bioscience and its competitors. This is 54% above median its historical median of 34.23. According to the industry distribution chart, Twist Bioscience ranks #97 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 50%.
Is Twist Bioscience's Gross Margin % too high?
Twist Bioscience's current Gross Margin % of 52.76% is 54% above median its 10-year median of 34.23. The Medical Diagnostics & Research industry median Gross Margin % is 51.78. Twist Bioscience's value of 52.76% is 1.9% above this industry median. Based on the distribution chart, Twist Bioscience ranks #97 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Gross Margin % compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #97 out of 194 companies for Gross Margin %. This puts Twist Bioscience in the upper half of its industry. The industry median Gross Margin % is 51.78. Twist Bioscience's value of 52.76% is 1.9% above this benchmark. While the company's 10-year median is 34.23 vs. the industry median of 51.78, Twist Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.78, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Gross Margin % of 52.76% is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Twist Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Gross Margin % is 52.76%, which is 54% above median its own 10-year median of 34.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (MIL:1TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.60, compared to a current price of €97.44 — trading 109.1% above its estimated fair value. The current Gross Margin % is 52.76%, which is 54% above median its 10-year median of 34.23 and 1.9% above the Medical Diagnostics & Research industry median of 51.78. Twist Bioscience's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Twist Bioscience (MIL:1TWST), the current Gross Margin % is 52.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (MIL:1TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €97.44 is trading 109.1% above its estimated GF Value™ of €46.60.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for MIL:1TWST:
Gross Margin %: 52.76% (54% above median its 10-year median of 34.23)
GF Value™: €46.60 vs. price of €97.44 (109.1% above fair value)
Industry Position: 1.9% above the Medical Diagnostics & Research median (#97 of 194)
No single metric tells the full story. See the MIL:1TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
47GF Score
Get the complete analysis for MIL:1TWST
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TWST has been successfully added to your 
